Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Blood|April 18, 2012
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetJoëlle Guilhot, Michele Baccarani, Richard E Clark, et al.Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.Blood|March 25, 2006
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialMats Brune, Sylvie Castaigne, John Catalano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.Blood|July 12, 2013
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registryMartin Höglund, Fredrik Sandin, Karin Hellström, et al.American Journal of Hematology|August 18, 2017
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITYStuart L Goldberg, Jorge E Cortes, Carlo Gambacorti-Passerini, et al.European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.The Hematology Journal : the Official Journal of the European Haematology Association|December 1, 2004
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survivalUlla Olsson-Strömberg, Bengt Simonsson, Tomas Ahlgren, et al.Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.British Journal of Haematology|August 16, 2002
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemiaHelene Hallböök, Bengt Simonsson, Thomas Ahlgren, et al.Pageof 4